Connection

JOHN KIRKWOOD to Lymphocyte Activation

This is a "connection" page, showing publications JOHN KIRKWOOD has written about Lymphocyte Activation.
Connection Strength

0.849
  1. Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
    View in: PubMed
    Score: 0.149
  2. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
    View in: PubMed
    Score: 0.095
  3. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011 Apr; 34(3):270-8.
    View in: PubMed
    Score: 0.079
  4. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother. 2010 Jul-Aug; 33(6):630-8.
    View in: PubMed
    Score: 0.075
  5. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol. 2010 Jun 15; 184(12):6709-18.
    View in: PubMed
    Score: 0.074
  6. NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
    View in: PubMed
    Score: 0.050
  7. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 Jan 01; 62(1):213-8.
    View in: PubMed
    Score: 0.041
  8. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
    View in: PubMed
    Score: 0.039
  9. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 Sep 01; 60(17):4946-52.
    View in: PubMed
    Score: 0.038
  10. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000 Jun 15; 88(12):2693-702.
    View in: PubMed
    Score: 0.037
  11. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 03 07; 4(5).
    View in: PubMed
    Score: 0.034
  12. CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a. Front Immunol. 2019; 10:14.
    View in: PubMed
    Score: 0.034
  13. Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry. 1996 Sep 01; 25(1):71-81.
    View in: PubMed
    Score: 0.029
  14. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015 Apr 15; 75(8):1635-44.
    View in: PubMed
    Score: 0.026
  15. Effects of interferon-gamma and tumour necrosis factor-alpha on the development of cytotoxic T lymphocytes in autologous mixed lymphocyte tumour cultures with human melanoma. Clin Exp Immunol. 1991 Oct; 86(1):163-72.
    View in: PubMed
    Score: 0.020
  16. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 01; 182(9):5240-9.
    View in: PubMed
    Score: 0.017
  17. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 01; 174(3):1751-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.